VivoSeq
Psychiatry

Bulimia Nervosa

19

Pipeline Programs↗

1

Active Trials↗

13

Companies Involved↗

Bulimia Nervosa is an emerging landscape with 19 programs across 13 companies. The most active players are Azurity Pharmaceuticals, Boehringer Ingelheim, Takeda. 4 therapies are approved with 1 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

45/100

Pipeline Velocity

6/100

Mech. Concentration

10/100

Completion Rate

58/100

Attrition Rate

29/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

A

Azurity Pharmaceuticals

1 program

Phase 2Boehringer Ingelheim logo

Boehringer Ingelheim

1 program

Phase 2Takeda logo

Takeda

1 program

Phase 2Novo Nordisk logo

Novo Nordisk

1 program

Phase 2E

Eastern Cooperative Oncology Group

1 program

Phase 2A

Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections

1 program

Phase 2

Pipeline

Programs by Phase

Analysis

Trial Status

14

clinical trials

Completed7 · 50%
Terminated3 · 21%
Suspended1 · 7%
Unknown status1 · 7%
Withdrawn1 · 7%
Recruiting1 · 7%

Clinical Trials

Trial Activity

14 trials

MDMA Assisted Therapy for Bulimia Nervosa: A Treatment Development Protocol
Recruiting·IIcahn School of Medicine at Mount Sinai·Phase 1·NCT07542145·40 enrolled
Neurobiology of Bulimia Nervosa
Completed·UUniversity of North Carolina, Chapel Hill·Phase 2·NCT04225221·10 enrolled
An Open Label Trial of Memantine in the Treatment of Bulimia Nervosa and Body Dysmorphic Disorder
Completed·MMclean Hospital·N/A·NCT01038128·5 enrolled
Effectiveness of Antibiotic Treatment for Reducing Binge Eating and Improving Digestive Function in Bulimia Nervosa
Completed·NNew York State Psychiatric Institute·Phase 2·NCT00304187·29 enrolled
Treatment of Bulimia Nervosa in a Primary Care Setting
Completed·National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)·N/A·NCT00009178
Effectiveness of Stepped Care Versus Best Available Care for Bulimia Nervosa
Completed·UUniversity of Minnesota·N/A·NCT00733525·293 enrolled
Effectiveness of Baclofen in the Treatment of People With Bulimia Nervosa or Binge Eating Disorder
Completed·NNew York State Psychiatric Institute·N/A·NCT00320047·10 enrolled
Evaluation of the Efficacy of Serotoninergic Antidepressants in Bulimia Nervosa, According to Brain Serotonin Profile Determined by Positron Emission Tomography With [18F] MPPF.
Completed·—·Phase 4·NCT02359513·51 enrolled
Neural Response to Catecholamine Depletion in Subjects Suffering From Bulimia Nervosa in Their Past and Healthy Controls
Suspended·UUniversity of Bern·N/A·NCT02179814·60 enrolled
N-acetylcysteine in the Treatment of Bulimia Nervosa
Terminated·LLindner Center of HOPE·Phase 3·NCT01033149·11 enrolled
N-acetylcysteine in Bulimia Nervosa
Terminated·LLindner Center of HOPE·Phase 2/3·NCT01131572·11 enrolled
Lisdexamfetamine for Adults With Bulimia Nervosa
Terminated·—·Phase 2·NCT03397446·23 enrolled
Topiramate Augmentation in Bulimia Nervosa Partial Responders
Withdrawn·NNeuropsychiatric Research Institute, Fargo, North Dakota·Phase 4·NCT00988481
Study on the Optimal Strategy of Chinese Patients With Bulimia Nervosa After Fluoxetine Treatment
Unknown status·SShanghai Mental Health Center·N/A·NCT04154813·550 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)